138 related articles for article (PubMed ID: 22409460)
1. Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.
Amato RJ; Stepankiw M
Future Oncol; 2012 Mar; 8(3):231-7. PubMed ID: 22409460
[TBL] [Abstract][Full Text] [Related]
2. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
Amato RJ
Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
[TBL] [Abstract][Full Text] [Related]
3. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients.
Harrop R; Shingler W; Kelleher M; de Belin J; Treasure P
J Immunother; 2010; 33(9):999-1005. PubMed ID: 20948436
[TBL] [Abstract][Full Text] [Related]
4. 5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy.
Amato RJ
Expert Opin Biol Ther; 2007 Sep; 7(9):1463-9. PubMed ID: 17727334
[TBL] [Abstract][Full Text] [Related]
5. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial.
Amato RJ; Shingler W; Goonewardena M; de Belin J; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
J Immunother; 2009 Sep; 32(7):765-72. PubMed ID: 19561532
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study.
Amato RJ; Hawkins RE; Kaufman HL; Thompson JA; Tomczak P; Szczylik C; McDonald M; Eastty S; Shingler WH; de Belin J; Goonewardena M; Naylor S; Harrop R
Clin Cancer Res; 2010 Nov; 16(22):5539-47. PubMed ID: 20881001
[TBL] [Abstract][Full Text] [Related]
8. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
[TBL] [Abstract][Full Text] [Related]
9. 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.
Cappuccini F; Pollock E; Stribbling S; Hill AVS; Redchenko I
Oncotarget; 2017 Jul; 8(29):47474-47489. PubMed ID: 28537896
[TBL] [Abstract][Full Text] [Related]
10. Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Scurr M; Pembroke T; Bloom A; Roberts D; Thomson A; Smart K; Bridgeman H; Adams R; Brewster A; Jones R; Gwynne S; Blount D; Harrop R; Wright M; Hills R; Gallimore A; Godkin A
JAMA Oncol; 2017 Oct; 3(10):e172579. PubMed ID: 28880972
[TBL] [Abstract][Full Text] [Related]
11. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Melcher A; Nicholls J; Wassan H; Habib N; Anthoney A
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4487-94. PubMed ID: 17671134
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial.
Amato RJ; Shingler W; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
Clin Cancer Res; 2008 Nov; 14(22):7504-10. PubMed ID: 19010868
[TBL] [Abstract][Full Text] [Related]
13. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.
Hanwell DG; McNeil B; Visan L; Rodrigues L; Dunn P; Shewen PE; Macallum GE; Turner PV; Vogel TU
J Immunother; 2013 May; 36(4):238-47. PubMed ID: 23603858
[TBL] [Abstract][Full Text] [Related]
14. Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer.
Tykodi SS; Thompson JA
Expert Opin Biol Ther; 2008 Dec; 8(12):1947-53. PubMed ID: 18990081
[TBL] [Abstract][Full Text] [Related]
15. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial.
Amato RJ; Drury N; Naylor S; Jac J; Saxena S; Cao A; Hernandez-McClain J; Harrop R
J Immunother; 2008; 31(6):577-85. PubMed ID: 18528296
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.
Kaufman HL; Taback B; Sherman W; Kim DW; Shingler WH; Moroziewicz D; DeRaffele G; Mitcham J; Carroll MW; Harrop R; Naylor S; Kim-Schulze S
J Transl Med; 2009 Jan; 7():2. PubMed ID: 19128501
[TBL] [Abstract][Full Text] [Related]
17. TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development.
Kim DW; Krishnamurthy V; Bines SD; Kaufman HL
Hum Vaccin; 2010 Oct; 6(10):784-91. PubMed ID: 20975327
[TBL] [Abstract][Full Text] [Related]
18. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors.
Mulryan K; Ryan MG; Myers KA; Shaw D; Wang W; Kingsman SM; Stern PL; Carroll MW
Mol Cancer Ther; 2002 Oct; 1(12):1129-37. PubMed ID: 12481437
[TBL] [Abstract][Full Text] [Related]
19. TroVax in colorectal cancer.
Rowe J; Cen P
Hum Vaccin Immunother; 2014; 10(11):3196-200. PubMed ID: 25483641
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
Acres B
J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
